| Ytd | ||
| 1y |
| Open | 0.37 | Prev Close | 0.37 | Low | 0.35 | High | 0.38 | Mkt Cap | 21.63M |
| Vol | 0.00 | Avg Vol | 1.35M | EPS | -0.81 | P/E | -0.45 | Forward P/E | -0.63 |
| Beta | 1.48 | Short Ratio | 9.52 | Inst. Own | 83.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.35 | 200-d Avg | 0.49 | 1yr Est | 7.00 |
ELEV News
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
NEW YORK , June 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investiga
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
BOSTON , June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncolog
-- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeti
-- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs acro
-- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentia
ELEV decides to stop developing its lead drug after disappointing data from an early-stage study eva
On Thursday, Elevation Oncology, Inc. ELEV elected to discontinue the development of EO-3021, a Clau
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payloa
-- Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combinati
BOSTON , Feb. 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncolo
-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combinat
Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in
-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – --
-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting
BOSTON , Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncolo
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR obs
Elevation Oncology (ELEV) might move higher on growing optimism about its earnings prospects, which
On Thursday, 1076 companies hit new 52-week lows.
On Thursday, 529 companies set new 52-week lows.
On Tuesday, 951 companies hit new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.